Keywords: ضد PD1; Uveitis; Drug induced uveitis; Posterior uveitis; Nivolumab; Anti-PD1; Chemotherapy; Check point inhibitors;
مقالات ISI ضد PD1 (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ضد PD1; immune checkpoint inhibitors; pneumonitis; thyroiditis; hypophysitis; anti-PD1; anti-CTLA-4;
Keywords: ضد PD1; cardio-oncology; checkpoint inhibitor; ipilimumab; myocarditis; nivolumab; pembrolizumab; anti-CTLA4; anti-cytotoxic T-lymphocyte-associated protein 4; anti-PD1; anti-programmed cell death protein 1; anti-PDL1; anti-programmed death-ligand 1; AUC; area un
Keywords: ضد PD1; Anti-PD1; Anti-CTLA4; Immune checkpoint inhibitors; Neurological adverse events;
Keywords: ضد PD1; B-Raf inhibitors; Mitogen-activated protein kinase inhibitor; Anti-Cytotoxic T-lymphocyte-associated protein 4; Anti-Programmed cell death-1; Metastatic melanoma; Cutaneous adverse event; Inhibidores de BRAF; Inhibidores de MEK; Anti-CTLA4; Anti-PD1; Mela
Keywords: ضد PD1; B-Raf inhibitors; Mitogen-activated protein kinase inhibitor; Anti-Cytotoxic T-lymphocyte-associated protein 4; Anti-Programmed cell death-1; Metastatic melanoma; Cutaneous adverse event; Inhibidores de BRAF; Inhibidores de MEK; Anti-CTLA4; Anti-PD1; Mela
Keywords: ضد PD1; Metastatic melanoma; Immunotherapy; CTLA-4; Blocking antibodies; Tremelimumab; Ipilimumab; Anti-PD1;
Uvéite bilatérale associée à un traitement par nivolumab
Keywords: ضد PD1; Dysfonctionnement meibomien; Chirurgie de la cataracte; Sécheresse oculaire; Meibographie; Expressibilité meibomienne; Uveitis; Drug induced uveitis; Posterior uveitis; Nivolumab; Anti-PD1; Chemotherapy; Check point inhibitors;
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
Keywords: ضد PD1; Non-small-cell lung cancer; PD-L1 expression; Circulating tumor cells; Monitoring of response; Immunotherapy; Anti-PD1;
Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer
Keywords: ضد PD1; Myeloid derived suppressor cells; Lung cancer; Anti-PD1; CCL2;
Le lymphome de Hodgkin : stratégies thérapeutiques actuelles et futures
Keywords: ضد PD1; Lymphome de Hodgkin; Radiothérapie involved-site; Brentuximab vedotin; Anti-PD1; Hodgkin lymphoma; Radiotherapy involved-site; Brentuximab vedotin; Anti-PD1 antibody;
Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer
Keywords: ضد PD1; Osteosarcoma; Myeloid derived suppressor cells; Anti-PD1; IL-18;
Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies
Keywords: ضد PD1; Anti-PD1; Anti-CD137; Abscopal effects; Brachytherapy;
Anti-PD1/PDL1 induced psoriasis
Keywords: ضد PD1; Anti-PD1; Psoriasis; Nivolumab; Pembrolizumab; Durvalumab;
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
Keywords: ضد PD1; Immunotherapy; Anti-PD1; Anti-PDL1; Response to conventional cancer treatment;
Immunothérapie et cancer du poumon : où en sommes-nous ?
Keywords: ضد PD1; Cancer du poumon; Immunité anticancéreuse; Anti-PD1; Anti-PD-L1; Vaccins anti-tumoraux; CTLA-4; Biomarqueurs; Lung cancer; Antitumor immunity; PD-L1 expression; PD1 inhibitors; PD-L1 inhibitors; Anti-tumor vaccines; CTLA-4; Biomarkers;
Resistance to PD1/PDL1 checkpoint inhibition
Keywords: ضد PD1; Immunotherapy; Resistance; Anti-PD1; Combination therapies; Checkpoint;
Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response
Keywords: ضد PD1; Brain metastases; Immunotherapy; Lesion response; Melanoma; SRS; Anti-CTLA 4; Anticytotoxic T-lymphocyte-associated protein 4; Anti-PD1; Antiprogrammed cell death protein 1; CI; Confidence interval; DBF; Distant brain failure; HR; Hazard ratio; IBM; Intac
Place des anti-PD1 dans la prise en charge des mélanomes cutanés
Keywords: ضد PD1; Mélanome métastatique; Pembrolizumab; Nivolumab; Immunothérapie; Anti-PD1; Mestastatic melanoma; Pembrolizumab; Nivolumab; Immunotherapy; Anti-PD1;
Immunothérapie : les checkpoints
Keywords: ضد PD1; Immunothérapie; Anti-CDLA4; Anti-PD1; Anti-PDL1; Points de contrôle immunitaires; Immunotherapy; Anti-CDLA4; Anti-PD1; Anti-PDL1; Immune checkpoints;